Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Anixa Biosciences

Tracked across 2 events · 12 articles · First seen Apr 02, 2026 · Last active Sep 21, 2026

Sentiment
10
Attention
2
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 10
Tech
Anixa Biosciences announced that Australia — Australian Government issued Patent Number 2020221280, a composition-of-matter patent titled Vaccine Adjuvants and Formulations, covering its breast cancer vaccine technology in Australia through 2040. The technology is exclusively licensed…
Impact: Anixa is the central actor, receiving the Australian composition-of-matter patent through 2040 for its breast cancer vaccine and expanding its global IP estate. The grant supports future regulatory and partnering prospects, though the stock traded down about 2 percent on the day.
Sep 21, 2026 · 6 articles
2 10
Business
Impact: Anixa Biosciences presented at the Biotech Resurgence conference, offering insights into its clinical development strategies and pipeline progress.
Apr 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Anixa Biosciences live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.